Development of chemotherapeutic treatment modalities resulted in a dramatic increase in the survival of children with many types of cancer. Still, in case of some pediatric cancer entities including rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma, survival of patients remains dismal and novel treatment approaches are urgently needed. Therefore, based on the concept of targeted therapy, numerous potential targets for the treatment of these cancers have been evaluated pre-clinically or in some cases even clinically during the last decade. This review gives an overview over many different potential therapeutic targets for treatment of these childhood sarcomas, including receptor tyrosine kinases, intracellular signaling molecules, cell cycle and apoptosis regulators, proteasome, hsp90, histone deacetylases, angiogenesis regulators and sarcoma specific fusion proteins. The large number of potential therapeutic targets suggests that improved comparability of pre-clinical models might be necessary to prioritize the most effective ones for future clinical trials. 
Introduction
About 12'000 children under 20 years of age are diagnosed each year with cancer in the US alone. Fifty years ago, such a diagnosis was a sentence of death for most patients due to the lack of effective therapies at that time and despite surgical resection of the tumor. This changed dramatically with the discovery of different cytotoxic chemotherapeutic agents able to kill proliferating cells which resulted in the development of effective therapies for many of these cancer types. Intensification of treatment and optimized treatment modalities, together with more effective palliative drugs to fight side effects, resulted in a continuous improvement of outcome in the second part of the last century. In the period 1996-2002 the overall 5-year survival rate has reached 79% (1) . For many of the pediatric cancer entities including Hodgkin lymphoma, retinoblastoma, Wilms tumor, and germ cell tumors, the survival rate nowadays even exceeds 90%.
However, for some other childhood cancer entities, chemotherapy still remains largely non-effective.
Resistance to the drugs and metastatic spread represent the two most important mechanisms for therapy failure. Tumors belonging to this group include different types of sarcomas such as rhabdomyosarcoma, Ewing's sarcoma or osteosarcoma which reach an overall 5-year survival rate of 60-65% (2) . Specific subgroups of these tumors with a tendency of early metastasis such as alveolar rhabdomyosarcoma even have a much poorer prognosis. In addition, intensive chemotherapeutic treatment can result in a variety of long-term sequelae in childhood patients, including impairment of growth and development, a variety of organ dysfunctions and subsequent secondary malignancies, preventing further intensification of therapy with these drugs (3) . Therefore, based on the plateau which has now been reached with current treatment options there is an urgent need for alternative, more targeted treatment approaches. This review will summarize some of the numerous recent developments in therapeutic approaches against childhood sarcomas with a special focus on rhabdomyosarcoma, Ewing's sarcoma and osteosarcoma.
Targeted therapy
To overcome problems associated with the unspecificity of the current therapeutic approaches, the concept of "targeted therapy" has been developed. Per definition, such an approach is based on the application of drugs (more) specifically targeting tumor cells and sparing normal cells. Two general approaches can be distinguished:
The first approach is based on differences in the physical presence of molecular markers between cancer and normal cells. Cancer-specific markers could serve as targets for antibodies or antibody-like molecules linked to cytotoxic agents which, upon binding, are able to kill these cells. Furthermore, immunological techniques may allow priming of specialized immune cells to recognize cancer-specific structures.
The second approach is based on differences in the dependency on certain functional characteristics between cancer and normal cells, which could be therapeutically exploited. Four different dependencies have been defined (4) . First, most cancer cells are dependent on the constant activity of only some of the underlying abnormalities ("oncogene addiction" or genetic dependence) (see also (5) ). Second, in some cancer cells mutation of one pathway renders these cells dependent on another pathway (synergy dependence). Third, cancer cells are often dependent on the same signaling pathways as their normal counterparts (lineage dependence). Fourth, single tumor cells or the tumor as a whole can depend on activities coming from the host environment such as angiogenesis or growth factors produced by stromal cells (host dependence). Numerous studies demonstrated that inhibition of activities involved in these dependencies can either inhibit cell proliferation or induce apoptosis in tumor cells but leaves normal cells more or less unaffected, suggesting that cancer cells are to a much greater extent dependent on these functions than normal cells. Therefore, all these dependencies represent potential targets for a cancer cell specific treatment.
Based on these concepts, identification of dependencies for each tumor entity or maybe even each patient is a crucial prerequisite for the development of future targeted therapies. The process of defining novel targets includes several crucial steps such as target identification based on experimental data including gene expression or mutational analysis. However, the main work should be a careful preclinical validation both in vitro with clear effects on cell viability and tumor growth and in vivo using different animal models.
Technological advances during the past decade in the area of genome and transcriptome analysis, including sophisticated gene expression analysis as well as high throughput sequencing methods, accelerated identification of potential targets substantially and resulted in a plethora of potential specific targets in all kinds of cancer entities. Also in childhood sarcoma many potential targets have been defined and some of them have been preclinically evaluated. A comprehensive list of potential molecular targets for treatment of childhood sarcoma is given in table 1 and will be discussed in detail in the following paragraphs.
Receptor Tyrosine Kinases
Transmembrane receptor tyrosine kinases (RTKs) are important upstream elements of signaling cascades which regulate cell growth, proliferation and survival. Many different RTKs are implicated in tumorigenesis of numerous cancer types (6) . Localization at the cell surface makes them accessible not only for small molecule inhibitors, but also for inhibitory antibodies, highlighting them as key targets for cancer treatment. Importantly, in normal tissue activity of most RTKs is only mandatory during embryonic development and not essential during adulthood (7). A series of RTKs has been linked to the development of childhood sarcomas including IGF1R, PDGFR, c-met and c-kit (8) . These RTKs have subsequently also been investigated as targets for therapy of these tumor types.
The IGF1R is one of the prototype targets in childhood sarcoma and has been extensively studied.
Although no activating mutations are known for this RTK, a plethora of studies have linked aberrant activity of this kinase to different cancers (for a general review see (9) ), for a sarcoma specific review see (10) ). In sarcomas, overexpression of the IGF1R itself, deregulated expression of ligands/ligand binding proteins or constitutive activation of downstream effectors might play a role. Different studies have evaluated the effect of IGF1R inhibition on growth of childhood sarcomas cell lines and xenografts, both with inhibitory antibodies and small molecule inhibitors (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . In these studies, blockade of IGF1R activity has been shown to affect cell proliferation, survival and anchorage-independent growth in vitro and tumorigenesis, tumor invasion and metastasis in vivo. Since it also sensitizes cancer cells to chemo-and radiotherapy in vivo, IGF1R is one of the prime targets for treatment of these sarcomas.
Indeed, the pre-clinical data initiated several clinical phase II trials which are currently ongoing and will evaluate the efficacy of IGF1R-targeting for pediatric sarcoma (Tab.2).
The significance of the other three RTKs mentioned as therapeutic targets is less well documented.
Numerous studies reported c-met expression in rhabdomyosarcoma and osteosarcoma (22) (23) (24) and cmet activity has been linked to regulation of proliferation, metastasis and resistance to chemotherapy in these tumors (25) (26) (27) (28) (29) . Furthermore, overexpression of HGF, the ligand for c-met, in an Ink4 null background leads to the development of RMS in mice (30) . In contrast, only few studies evaluated c-met as target for therapy. SiRNA-based silencing of c-met by was found to inhibit proliferation, invasiveness, and anchorage-independent growth in vitro, and reduce tumor mass in a xenograft model of rhabdomyosarcoma (31) . In a second study, the c-met inhibitor K252a was able to revert HGF dependent growth of osteosarcoma cell lines (25) . However, based on promising findings obtained in numerous preclinical studies with c-met inhibitors for treatment of adult tumors (32) , further evaluation of c-met in childhood sarcomas might be indicated.
PDGFR is expressed in all three types of childhood sarcomas discussed here (33) (34) (35) and c-kit expression has been found in Ewing's sarcoma and osteosarcoma (36) (37) (38) . Mutations were only found in the case of c-kit and in a small fraction of Ewing's sarcomas (39) . However, both PDGFR and c-kit are activated in these childhood sarcomas (37, 40) and PDGF was found to act as mitogen for osteosarcoma cells (41) . Furthermore, expression of PDGF-AA was found to be associated with tumor progression in osteosarcoma (42) . Based on these findings, preclinical studies evaluated the effects of PDGF and c-kit inhibitors on sarcoma cell growth. However, results from these studies are rather conflicting. Some studies demonstrated that imatinib, which inhibits both PDGFR and c-kit, is able to inhibit growth of Ewing's sarcoma, osteosarcoma or rhabdomyosarcoma cells in vitro and as xenografts in vivo with a high IC 50 of 6-15 μM (34, 36, (43) (44) (45) . In contrast, IC 50 -concentrations of imatinib necessary to inhibit ligand induced phosphorylation of PDGFR and c-kit were in the range of 0.1-0.5 μM (44, 46) . Only in one study using osteosarcoma cells, imatinib concentrations necessary for inhibiting PDGFR phosphorylation and inhibition of proliferation in vitro corresponded (41) . However, in this case imatinib had no effect on growth of xenografts. Furthermore, sunitinib, which also inhibits PDGFR and c-kit among a range of other kinases, inhibited growth of most childhood sarcomas as xenografts, but its effect was attributed to inhibition of angiogenesis (47) . Despite these conflicting data, a phase II clinical study testing imatinib for the treatment of different tumors including Ewing's sarcoma and osteosarcoma was carried out by the Children's Oncology group. Imatinib demonstrated no activity as single agent, although drug concentrations were again well above the levels necessary for PDGF or c-kit inhibition (48) . Taken together, these data suggest that the effects detected in vitro might be due to off target effects and that PDGF and c-kit might not be relevant targets for treatment of these childhood sarcomas.
The use of siRNA-mediated silencing of target expression, which is far more specific than the use of small molecule inhibitors with an often ill-defined spectrum of activities, might be of help in future preclinical studies to demonstrate dependence of sarcoma growth on activity of PDGFR and c-kit receptor. In childhood sarcoma one research focus as target for therapy is mTOR. mTOR activation as assessed by its phosphorylation has been detected among all childhood sarcoma entities discussed here and was negatively correlated with rhabdomyosarcoma survival (54-56). Inhibition of mTOR by Rapamycin or derivatives thereof inhibited proliferation of childhood sarcoma cells in vitro (55, 57, 58) and also inhibited the growth of xenografts of rhabdomyosarcoma and osteosarcoma cell lines in vivo (58, 59) . In vitro the mechanisms of action has been reported to dependent on the p53/p21 status. Cells expressing wild-type p53 or p21 arrest in G1 whereas cells lacking functional p53/p21 undergo apoptotic cell death (57, 60) . In vivo, part of the growth inhibitory effect seems to be caused by inhibition of angiogenesis via downregulation of mTOR-regulated expression of VEGF (59, 61). A similar link has also been found in other tumors (62) and may explain some discrepancies between moderate in vitro sensitivity and high in vivo responsiveness of some cell lines (58) . Different clinical phase I/II studies with Rapamycin derivatives for the treatment of childhood solid tumors have been started (Tab.2). Initial data demonstrated good tolerability of Everolimus at doses effective for inhibition of mTOR (63) .
Intracellular signaling molecules
Interestingly, in rhabdomyosarcoma cells inhibition of mTOR signaling triggers a negative feedback loop which activates AKT via IGF1R signaling and acts protective against mTOR signaling (64, 65) . Hence, a combined inhibition of mTOR and IGF1R activity resulted in an additive inhibition of cell growth for all sarcoma types discussed here (64) (P.Houghton et al, education book AACR 2008). These experiments suggest that combining mTOR and IGF1R inhibitors may be superior for childhood sarcoma therapy compared to mTOR inhibitors alone.
Cell cycle regulators
Cell cycle progression is the basis for cancer cell proliferation, highlighting regulators of the cell cycle machinery as interesting targets for therapeutic intervention (for review see (66) , p27 KIP1 and p57 KIP2 have been reported in these sarcomas (71) (72) (73) (74) (75) (76) . Since the frequency of deletions is generally much higher in cell lines compared to primary tumors (73, 77) , some of these aberrations might be acquired in vitro.
Therefore, careful evaluation of preclinical models is necessary to generate data useful in terms of translation to a clinical study.
Different CDK inhibitors including the Pan-CDK inhibitor flavopiridol, roscovitine, PD0332991 or merolins demonstrated to be effective against the growth of Ewing's sarcoma, rhabdomyosarcoma and osteosarcoma cell lines in vitro and as xenografts in vivo (78) (79) (80) (81) (82) . Importantly, flavopiridol has been
shown to be only a weak substrate for proteins involved in cell detoxification such as P-glycoprotein (Pgp) (83) and was also effective against drug-resistant osteosarcoma and Ewing's sarcoma cells expressing P-gp and multidrug resistance-associated protein 1 (78) . A phase I trial has been carried out in paediatric sarcomas with flavopiridol assessing clinical safety (Tab.2) (84). On the other hand, in a clinical phase II study using flavopiridol for the treatment of different soft tissue sarcomas in adult patients, no objective responses were seen (85) .
Apoptosis Pathways
Impaired apoptosis plays a key role in pathogenesis of cancer by allowing cancer cells to escape One strategy to antagonize the apoptotic block is to restore functional forms of mutated or lost proapoptotic proteins. In sarcoma cells restoration of functional p53 by adenoviral transduction has been found in different studies to enhance drug-induced apoptosis (86) (87) (88) . However, transfer of such approaches to the clinics depends on the development of safe and efficient methods for gene transfer and therefore might not be available for patients in the near future.
Another strategy to induce apoptosis in cancer cells is to inhibit anti-apoptotic proteins. In childhood sarcomas, inhibition of the Bcl-2 family of proteins was investigated. Unfortunately, the small molecule Bcl-2 family protein inhibitor ABT-263, which is otherwise known to display cytotoxicity against different tumor types, demonstrated only limited activity against different sarcoma xenografts as single agent (89) .
A third apoptosis promoting strategy is activation of the extrinsic apoptosis pathway through members of the TNF family of death-inducing ligands including TNF, Fas ligand (FasL) and TNF-related apoptosis inducing ligand (TRAIL). These proteins are able to induce apoptosis in different cancer entities. While TNF and FasL cause severe liver toxicity and are therefore not useful for clinical application, TRAIL does not have this drawback (90, 91) and is the most promising therapeutic agent within this group (90, 92) showing a good therapeutic window between normal and cancer cells, for so far unknown reasons 
Hsp90
Hsp90 is a molecular chaperone involved in correct folding of specific client proteins. as well as on tumor growth in vivo (116) . Similarly, for Ewing's sarcoma one report demonstrated efficacy of 17-AAG against cell proliferation and xenograft growth alone or in combination with IGF1R inhibitors (117), whereas another study using Alvespimycin reported only effects on in vitro growth of Ewing's sarcoma cell lines but not in xenografts (116) . Also only moderate effects were found for osteosarcoma in single treatments, however in this case combination with cisplatin demonstrated to be synergistic (118) . Taken together, although the biological basis for the responsiveness of some childhood sarcoma cell lines toward hsp90 inhibition is currently unknown, these data support further preclinical evaluations in some childhood sarcoma entities, especially rhabdomyosarcoma.
Histone Deacetylases
Acetylation and deacetylation of histones alters higher order chromatin structure by influencing histone interaction with DNA. Histone acetylation is regulated by the balance of histone actetyltransferases Among the different childhood sarcomas, Ewing's sarcoma seems especially adequate for treatment with HDACIs. Expression of the fusion protein EWS-FLI1, on which Ewing's sarcoma cells depend, has been shown to be negatively influenced by HDACIs (122) . Furthermore, EWS-FLI1 was found to deregulate histone acetylation by both repressing HAT activity and upregulating HDAC activity by, at least in part, interacting with p300 and thereby inhibiting its HAT activity (123) . These data suggest that deregulation of histone acetylation might play a specific role in tumorigenesis of Ewing's sarcoma.
Indeed, a series of preclinical studies demonstrated activity of HDACIs against Ewing's sarcoma in vitro
and in vivo (122) (123) (124) (125) . Anti-proliferative effects were also found for osteosarcoma in vitro and in vivo (125) (126) (127) , and against rhabdomyosarcoma in vitro (125, 128) . Mechanisms of growth inhibition are not fully understood and may differ in each combination of reagent and tumor cells. However, although clinical anti-cancer activity was found in single treatment approaches, it was generally suggested that
HDACIs might produce the best clinical effects in combination with other agents (121) . In this respect, HDACIs were reported to sensitize osteosarcoma and Ewing's sarcoma cells to death receptor mediated apoptosis via different mechanisms (124, 129, 130) . Furthermore, combination of HDACIs with an inhibitor of DNA methylation (5-aza-2`-deoxycytidine) was found to act synergistic in Ewing's sarcoma cells (131) and combination with genistein was synergistic in osteosarcoma cells (127) .
However, in some drug-resistant osteosarcoma or Ewing's sarcoma cells the cyclic tertrapeptide subfamily of HDACIs only displayed an effect on cell growth in combination with inhibitors of drug efflux systems (132) , suggesting that resistance mechanisms to HDACI have to be taken into account.
Angiogenesis
To grow to sizes beyond 1-2 mm 
Cancer specific fusion proteins
A characteristic of different childhood sarcomas is the presence of specific chromosomal translocations leading to expression of chimaeric fusion proteins, including EWS/FLI1, EWS/ERG and others in Ewing's sarcoma and PAX3(7)/FKHR in alveolar rhabdomyosarcoma (152). Ewing's sarcoma and rhabdomyosarcoma cells have been found to be addicted to the activity of these fusion proteins (153, 154) , suggesting that blocking this activity could be a possible therapeutic strategy. Moreover, these proteins are strictly cancer cell specific and therefore represent ideal targets for targeted therapy. Until antisense oligonucleotides and siRNA-based approaches will be clinically established, immunotherapeutical approaches may be best suited to target these fusion proteins for therapy.
Although established tumors usually escape patient immunosurveillance, the immune system is potentially able to recognize and reject tumors (155) and there is preliminary evidence that different manipulations of the immune system can exert a clinical benefit in selected settings (156) (157) (158) . Since the final effector against tumor cells is in most models a CD8+ T cell, the majority of cancer immunotherapy efforts are devoted to stimulating cellular immune responses.
In suggesting that a trial for such an approach might be applicable for therapy of rhabdomyosarcoma.
An alternative to immunological approaches might be pharmacological inhibition of the fusion proteins.
Unfortunately, the fusion proteins in case of Ewing's sarcoma and rhabdomyosarcoma are composed of parts of transcription factors which might not be easily druggable by small molecule inhibitors. However, recent findings demonstrating that PAX3/FKHR activity is regulated by phosphorylation (163) suggest that the activity of such fusion proteins might be inhibited indirectly by inhibition of important posttranslational modifications such as phosphorylation. Since most transcription factors might be regulated by phosphorylation (164) , this strategy might also be applicable to other fusion proteins. Small molecule inhibitors for upstream kinase(s) of these key molecules might therefore be used for treatment of the respective tumors.
Perspective
In the last few years many novel drugs against childhood sarcomas have been tested in preclinical studies. Many of these compounds might not be used as stand alone drugs but in combination with a second, specifically targeting or conventional drug, thereby further increasing the number of potential therapeutic approaches. In sharp contrast to the large number of potential novel therapies, the incidence of these tumors is per se rather low. Therefore, the number of childhood sarcoma patients eligible for evaluation of novel, experimental therapies is small and only a small subset of pre-clinically efficient drugs might be tested also in a clinical setting. Thus, the most promising of these should be prioritized based on available preclinical data. However, for such a selection process some important aspects have to be taken into account. A second important attribute of preclinical models, beside their comparability, is their validity to predict the performance of a compound in the clinics. In case of conventional chemotherapeutic drugs in vitro cell line and xenograft models have been found to be predictive in some but not all cases (166, 167) .
Since conventional chemotherapeutics act on unspecific molecular components such as DNA or cytoskeleton, the efficacy of these compounds might rely to a lesser extent on very accurate representation of the specific tumor characteristics compared to very specific targeting compounds. It is obvious that cell line and xenograft models represent only approximations of the primary tumor and are not able to reproduce all tumor characteristics in detail, particularly not the influence of a specific A potential alternative might be the usage of primary patient material as xenografts in the mouse for preclinical treatment trials. For that, small pieces of primary tumor material sampled by biopsy or surgery would first be transplanted into a set of mice for amplification. The amplified material then could be stored in liquid nitrogen or used for secondary transfers into a second set of mice used for treatment studies. However, also this approach requires a representative number of patients for a given tumor type.
Nevertheless, only a small fraction of novel compounds has been tested in the clinics so far. Many additional drugs including vast numbers of combinations are ready for clinical testing and will eventually help to improve outcome of childhood cancer. It is therefore reasonable to assume that, in addition to improved survival rates achieved with conventional chemotherapeutics in the last 30 years, a further increase in survival rates for many childhood malignancies lies ahead of us with hopefully simultaneous decrease of side effects. [187] Notch [188] MUC18 [189] CTLA-4 [190] Hedgehog [191] Intracellular signaling molecules mTor [57-59] PDK-1/AKT [175] Src [176] Mek/Erk [177] [178] Estrogen receptor [179] Mirk/Dyrk1B [180] Smad4 [181] Retinoic acid [182] mTOR [58] Src [176] Lyn [186] mTor [55, 58] c-jun [192] [193] Src [176, 198] Stathmin [194] [195] α-CaMKII [196] Cell cycle Targets discussed in the text are written in bold. 
